Clinicopathologic and immunohistochemical study of early colorectal cancer with liver metastases

Journal of Gastroenterology

Volumn 34, Issue 3, 1999, Pages 334-340

  Okano, Keiichi ^a   Shimoda, Tadakazu ^b   Matsumura, Yasuhiro ^b  

^a National Cancer Hospital   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

CD44; Early colorectal cancer; Liver metastases; Mucin; P53

Indexed keywords

CD44V ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; EARLY CANCER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME;

ADENOCARCINOMA; AGED; ANTIGENS, CD44; BIOPSY, NEEDLE; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032805848     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350050270     Document Type: Article

References (22)

1. Almersjo O, Bengmark S, Hafstrom L. Liver metastases found by follow-up of patients operated on for colorectal cancer. Cancer 1976;37:1454-7.
2. Blumgart LH, Allison DJ. Resection and embolization in the management of secondary hepatic metastases. World J Surg 1982;6:32-45.
3. Kodaira S, Yao T, Nakamura K, Watanabe E, Maruyama M, Ushio K, et al. Multi-institutional survey of sm colorectal cancer with metastases (in Japanese with English abstract). Stomach and Intestine 1994;29:1137-42.
4. Japanese Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of the colon, rectum and anus. 5th ed. Tokyo: Kanehara, 1994.
5. Shimoda T,. Ikegami M, Fujisaki J, Matsui T, Aizawa S, Ishikawa E. Early colorectal carcinoma with special reference to its development de novo. Cancer 1989;64:1138-46.
6. Borgya A, Woodman A, Sugiyama M, Donie F, Kopetzki E, Matsuyama Y, Tarin D. Isolation and characterization of antibodies which specially recognize the peptide encoded by exon 7 (v2) of the human CD44 gene. Clin Mol Pathol 1995;48:M241-50.
7. Fortner J, Kim D, Maclean B, Barrett M, Iwatsuki S, Turnbull A, et al. Major hepatic resection for neoplasia: personal experience in 108 patients. Ann Surg 1978;188:363-71.
8. Coppa G, Eng K, Ranson J, Gouge T, Localio S. Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors. Ann Surg 1985;202:203-8.
9. Adson M, Heerden J. Major hepatic resection for metastatic colorectal cancer. Ann Surg 1980;191:576-83.
10. Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzeti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991;78:797-801.
11. Nagai E, Yao T, Sakamoto M, Akazawa K, Utsunomiya T, Tsuneyoshi M. Risk factors related to liver metastasis in colorectal cxarcinoma: a multivariate analysis of clinicopathologic and immunohistochemical variables. Jpn J Cancer Res 1994;85:1280-7.
12. Banks L, Matlashewski G, Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;41:178-83.
13. Pricolo V, Finkelstein S, Hansen K, Cole B, Bland K. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 1997;132:371-5.
14. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki Y. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2778-84.
15. Scott N, Sagar P, Stewart J, Blair G, Dixon M, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991;63:317-9.
16. Kawasaki Y, Monden T, Morimoto H, Murotani M, Miyoshi Y, Kobayashi T, et al. Immunohistochemical study of p53 expression in microwave fixed, paraffin embedded section of colorectal carcinoma and adenoma. Am J Clin Pathol 1992;97:244-9.
17. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44, a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989;10:423-8.
18. Herrlich P, Zoller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993;14: 395-9.
19. Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, et al. Expression of a CD44 variant containing exon 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 1996;14:1122-7.
20. Nihei Z, Ichikawa W, Kojima K, Togo S, Miyanaga T, Hirayama R, Mishima Y. The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today 1996;26:760-1.
21. Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 1994;106:353-61.
22. Osako M, Yonezawa S, Yamashita K, Shimizu T, Tanaka S, Mizouchi J, et al. Immunohistochemical studies of mucin antigens in pancreas and intrahepatic bile-duct tumors. J Hepatobiliary Pancreat Surg 1997;4:149-56.